Lucentis (ranibizumab) / Roche, Novartis, Santen, China Medical System - LARVOL DELTA

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov) - P3 | N=561 | Recruiting | Sponsor: AbbVie

Adverse events • Real-world evidence • Trial initiation date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Effects of Subconjunctival Bevacizumab and Ranibizumab on Corneal and Systemic Oxidative Stress Biomarkers in an Alkali Injury Model. (PubMed, Life (Basel)) - "The two anti-VEGF agents caused numerical changes in corneal oxidative parameters, but these changes did not achieve statistical significance. The research requires further investigation to understand potential agent-related effects on corneal redox balance, which should take place in larger, more detailed studies."

Biomarker • Journal

Cost-effectiveness analysis of the use of faricimab in diabetic macular edema in China. (PubMed, J Comp Eff Res) - "Faricimab, administered according to a personalized treatment interval regimen following four initial monthly injections, was compared with aflibercept (every 8 weeks) and with ranibizumab and conbercept (both following a pro-re nata dosing regimen). Sensitivity analyses confirmed the robustness of these results, consistently demonstrating faricimab as a dominant and cost-effective treatment option for DME. This first Chinese cost-effectiveness study of faricimab for DME shows it enhances visual outcomes and reduces costs, supporting its adoption and providing evidence for healthcare decision-making on reimbursement and resource allocation."

HEOR • Journal • Diabetes • Diabetic Macular Edema • Metabolic Disorders • Ophthalmology

EFFECTS OF FARICIMAB LOADING PHASE ON DIABETIC MACULAR EDEMA IN REAL-WORLD SETTING: An Optical Coherence Tomography Angiography Study. (PubMed, Retina) - "Faricimab loading phase showed promising results in visual outcomes and structural improvement in resistant diabetic macular edema."

Journal • Real-world evidence • Cardiovascular • Diabetic Macular Edema • Ophthalmology • Retinal Disorders

Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction. (PubMed, JAMA Ophthalmol) - "Sensitivity analyses restricted exposure to 14 days or fewer pre-CVE and compared aflibercept, bevacizumab, or ranibizumab with other agents. Results of this cohort study reveal that peri-CVE anti-VEGF was not associated with increased mortality or morbidity. Outcomes did not differ among commonly used agents, supporting the safety of continuing intravitreal anti-VEGF therapy without modification during the peri-CVE period."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction

Comparison of the clinical effect of intravitreal ranibizumab and intravitreal dexamethasone implants in the treatment of retinal vein occlusion complicated with macular oedema: a meta-analysis. (PubMed, BMC Ophthalmol) - No abstract available

Journal • Retrospective data • Macular Edema • Ophthalmology • Retinal Vein Occlusion

Delayed anti-vascular endothelial growth factor therapy in patients with type 2 diabetes mellitus and branch retinal vein occlusion-associated macular edema negatively affects visual outcomes. (PubMed, Front Endocrinol (Lausanne)) - "This single-center retrospective cohort study included 148 patients diagnosed with BRVO-ME and receiving their first intravitreal ranibizumab injection between January 2024 and May 2025...Initiation of anti-VEGF therapy within seven days of diagnosis is associated with greater six-month visual improvement in patients with BRVO-ME and T2DM. Delayed treatment may contribute to suboptimal visual recovery."

Journal • Retrospective data • Diabetes • Macular Edema • Metabolic Disorders • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Type 2 Diabetes Mellitus

Myocardial Infarction, Stroke, and Death after Intravitreal Injection of Anti-VEGF in a Nationwide Study. (PubMed, Ophthalmol Sci) - "In the stratified analysis of aflibercept and ranibizumab IVT, no difference was found in the risk for the main outcome between the 2 agents. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."

Journal • Cardiovascular • Cataract • Diabetes • Metabolic Disorders • Myocardial Infarction • Ophthalmology

Urinary biomarkers and serum VEGF in preterm infants with retinopathy of prematurity treated with ranibizumab. (PubMed, Pediatr Int) - "IVR treatment did not show the sustained renal injury or suppress serum VEGF levels in preterm infants with ROP."

Biomarker • Journal • Acute Kidney Injury • Nephrology • Renal Disease • Retinal Disorders • Retinopathy of Prematurity • FABP1 • PODXL • VEGFA

A novel PD-1xVEGFxCTLA-4 tri-specific antibody, BSI-551, demonstrates potent efficacy and favorable safety in preclinical tumor models (AACR 2026) - "Here, we report the development and preclinical activity of this new therapeutic. BSI-551 was generated based on the sequences of in-house PD-1 antibody BSI-050, anti-VEGF antibody ranibizumab, and anti-CTLA-4 antibody tremelimumab...In a CRC cancer model (HT-29), treatment with BSI-551 resulted in a significant tumor regression and better tumor growth inhibition (TGI) as compared to combo treatment of pembrolizumab, ipilimumab and bevacizumab. In conclusion, BSI-551 demonstrates significant potential as a next-generation I/O therapy designed to be effective in tumors with poor responses to current monotherapies. Further pharmacokinetics, toxicity, and IND-enabling studies of BSI-551 are underway."

IO biomarker • Preclinical • Trispecific • Oncology • CD4 • CD8 • CD80 • FAT4 • IL2

Effectiveness Of Ultrathin 40-Gauge Needles for Intravitreal Injections. (PubMed, Korean J Ophthalmol) - "Injections (0.05 mL bevacizumab, ranibizumab, or aflibercept) were administered in an operating room by a single surgeon following Avery et al.  Using an ultrathin 40 G needle for IVIs significantly reduces patient‑reported pain and vitreous reflux without increasing subconjunctival hemorrhage. These findings support the integration of 40 G needles into routine IVI practice to enhance long-term patient adherence and treatment efficacy."

Journal • Age-related Macular Degeneration • Diabetic Macular Edema • Hematological Disorders • Macular Degeneration • Ophthalmology • Pain • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Real-world cost evaluation of conbercept vs. ranibizumab for retinal and choroidal vascular diseases from 2021 to 2024: evidence from societal and medical insurance perspectives. (PubMed, BMC Public Health) - No abstract available

Journal • Real-world evidence • Reimbursement • US reimbursement • Cardiovascular

VOYAGER: A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (clinicaltrials.gov) - P=N/A | N=6000 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Trial primary completion date: Mar 2027 ➔ Nov 2026

Real-world evidence • Trial primary completion date • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (clinicaltrials.gov) - P3 | N=510 | Completed | Sponsor: Laboratorios Sophia S.A de C.V. | Recruiting ➔ Completed

Head-to-Head • Trial completion • Diabetic Macular Edema • Ophthalmology

Measurement of Acute Intraocular Pressure Elevation Immediately After Intravitreal Anti-VEGF Injection and Analysis of Prefilled Syringe Accuracy. (PubMed, Clin Ophthalmol) - "The anti-VEGF agents including aflibercept 2 mg, aflibercept 8 mg, brolucizumab, faricimab, and ranibizumab-BS were assessed. Intravitreal injection using the aflibercept 2 mg prefilled syringe may deliver approximately 1.5 times the intended volume into the eye. This may raise safety concerns, such as the risk of transient vision loss due to marked immediate IOP elevation, and may also affect clinical outcomes and the validity of clinical trials."

Journal

Use of Aflibercept to Treat Retinopathy of Prematurity in Children with Extremely Low Birth Weight. (PubMed, J Clin Med) - "Background: Aflibercept is one of the anti-VEGF drugs used, among others, for the treatment of retinopathy of prematurity, alongside the widely used bevacizuab and ranibizumab...Currently, large studies (e.g., Firefleye and Butterfleye) describe the effects of a new aflibercept therapy at a dose of 0.4 mg. Studies on aflibercept obviously require further observations, so all reports, even from small groups, are important."

Journal • Anesthesia • Bronchopulmonary Dysplasia • Cataract • Critical care • Hematological Disorders • Infectious Disease • Ophthalmology • Pulmonary Disease • Respiratory Diseases • Retinal Disorders • Retinopathy of Prematurity • Septic Shock • FLT1 • KDR

Synergistic inhibition of macular vascular permeability in diabetic edema: Ginsenoside Rg3 enhances ranibizumab efficacy by targeting angiopoietin-like protein 4 and vascular endothelial growth factor via neuropilin/RhoA signaling. (PubMed, J Diabetes Investig) - "The combination of ginsenoside Rg3 and ranibizumab effectively antagonizes ANGPTL4 and VEGF and regulates the NRP/RhoA pathway, significantly reducing vascular permeability in DME through synergistic action. This provides crucial theoretical support for novel DME combination therapy."

Journal • Diabetic Macular Edema • Inflammation • Ophthalmology • ANGPTL4 • NRP1 • RHOA

Characterizing the Treatment Courses of Ranibizumab and Panretinal Photocoagulation for Retinopathy of Prematurity. (PubMed, J Pediatr Ophthalmol Strabismus) - "Final outcomes included PRP for persistent avascular retina in 22 (30.6%) eyes, unknown final outcomes due to lost follow-up for 16 (22.2%), documented resolution in 33 (45.8%), and scleral buckling for a peripheral retinal detachment (stage 4a) for one (1.4%). Ranibizumab was initiated at a younger age with higher retreatment and reactivation events compared to PRP, underscoring variability in real-world ROP treatment patterns and outcomes."

Journal • Retinal Disorders • Retinopathy of Prematurity

Perioperative anti-vascular endothelial growth factor treatment in diabetic vitrectomy: A narrative review. (PubMed, Indian J Ophthalmol) - "This review also elaborates the various intraoperative and postoperative benefits of anti-VEGFs with regard to the duration of vitrectomy, intraoperative bleeding, iatrogenic breaks, need for endodiathermy and silicon oil endotamponade, surgical difficulty score, postoperative visual gain, intraocular pressures, postoperative vitreous cavity hemorrhage, and need for second surgery. The current narrative also mentions the potential ocular adverse effects of anti-VEGF, such as progression of tractional retinal detachment, apart from addressing other ocular side effects and a few other uncommon yet serious systemic adverse events."

Journal • Diabetes • Diabetic Retinopathy • Hematological Disorders • Metabolic Disorders • Retinal Disorders

EFFICACY OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS IN PATIENTS WITH DIABETIC MACULAR OEDEMA AND HYPERTENSION: POST HOC SUBGROUP ANALYSIS OF THE COMET TRIAL (ATTD 2026) - "Participants were randomized to receive either SGLT2 inhibitor (luseogliflozin) or sulfonylurea (SU, glimepiride). The primary outcome was the treatment burden, quantified by the total number of intravitreal ranibizumab injections (IVRs) over 48 weeks. Within the OSBP ≥140 mmHg subgroup, 14 patients received SGLT2 inhibitor and 15 received SU... SGLT2 inhibitor may help reduce the treatment burden of IVRs in patients with DMO and elevated OSBP. The improvements in blood pressure and visual acuity, despite fewer injections, indicate a potential synergistic effect of SGLT2 inhibitor in managing hypertensive DMO. Further investigation is warranted to validate its efficacy as a non-invasive therapeutic option."

Clinical • Retrospective data • Cardiovascular • Diabetic Macular Edema • Hypertension • Macular Edema • Ophthalmology

Efficacy of a single dose switch from aflibercept to ranibizumab in the treatment of neovascular age-related macular degeneration. (PubMed, PLoS One) - "Our study indicates that changes in CMT are affected by age, the number of previous injections, and the time interval between visits. These biomarkers may offer valuable insights for future research on switching anti-VEGF drugs to optimize treatment strategies for nAMD. A single dose treatment switch to ranibizumab yielded non-inferior outcomes."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Efficacy and factors associated with reactivation following intravitreal ranibizumab or conbercept for retinopathy of prematurity. (PubMed, Front Med (Lausanne)) - "A lower PMA at initial treatment and Zone I ROP were identified as significant risk factors for reactivation. Infants with these characteristics require closer and more prolonged follow-up after anti-VEGF therapy."

Journal • Retinal Disorders • Retinopathy of Prematurity

Efficacy and safety of conbercept, ranibizumab and laser in retinopathy of prematurity: a systematic review and network meta-analysis. (PubMed, Surv Ophthalmol) - "Dose-response analysis revealed 0.25mg conbercept balanced efficacy (82.70% inactivity) and safety (3.84% AEs), while 0.3mg showed peak efficacy (90.7%) but limited safety data. Higher doses reduced recurrence (22.97% at 0.15mg vs 17.00% at 0.25mg)."

Journal • Retrospective data • Review • Cardiovascular • Hematological Disorders • Retinal Disorders • Retinopathy of Prematurity

Intravitreal dexamethasone implant in epiretinal membrane-associated diabetic macular edema refractory to anti-VEGF therapy: a visual performance and retinal ultra-structural analysis. (PubMed, Eur Rev Med Pharmacol Sci) - "DEX implant could be a reliable and effective therapeutic alternative for ERM-associated DME resistant to anti-VEGFs, particularly during the first 3 months of treatment, when it appears to be most effective. A single DEX implant can produce a satisfactory and reasonably safe response, and the treatment can be repeated even after the implant's potency has gradually declined. Importantly, improved BCVA and retinal ultra-structure following DEX implant could lessen the need for ERM surgery and multiple intravitreal anti-VEGF injections. If ERM-associated DME persists despite multiple DEX implants, surgery should be considered."

Journal • Diabetes • Diabetic Macular Edema • Glaucoma • Metabolic Disorders • Ophthalmology • Retinal Disorders • Type 2 Diabetes Mellitus

Choroidal neovascularization secondary to punctate inner choroidopathy after resolution of multiple evanescent white dot syndrome: A case report. (PubMed, Medicine (Baltimore)) - "MEWDS and PIC may share common etiological and pathogenetic mechanisms. PIC may develop sequentially after MEWDS in the same eye, and CNV may be a complication of PIC. A combination of oral corticosteroid therapy for PIC and timely intravitreal anti-VEGF injections for secondary CNV can achieve favorable long-term clinical outcomes. Regular follow-up is necessary for patients with MEWDS to monitor for potential progression to PIC and CNV."

Journal • Hematological Disorders • Ophthalmology • Retinal Disorders